Short answer
Cullinan Therapeutics, Inc. (CGEM) filed an 8-K current report with the SEC on September 24, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Q4 2026 milestones update signals upcoming clinical and corporate catalysts for Cullinan Therapeutics.
Cullinan Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Q4 2026 milestones update signals upcoming clinical and corporate catalysts for Cullinan Therapeutics
- Press release furnished as Exhibit 99.1 contains the milestone details investors should review
- Regulation FD disclosure indicates the information was publicly disseminated to ensure broad investor access
Item 8.01 · Other Events
- Fourth-quarter 2026 catalysts span CLN-978 immunology data across SLE, RA and Sjögren’s disease
- December CLN-978 readouts include multi-dose and single-target regimens from three ongoing Phase 1 trials
- Velinotamig Phase 1 SLE multi-dose data expected at ACR Convergence 2026 in November
- December CLN-049 Phase 1 dose-escalation update targets relapsed/refractory acute myeloid leukemia
Item EX-99.1 · Exhibit EX-99.1
- Q4 2026 catalyst slate centered on clinical updates across autoimmune disease and oncology T-cell engager programs
- CLN-978 multi-dose and single-dose data in SLE, RA, and Sjögren’s disease expected in December
- Velinotamig SLE multi-dose data scheduled for ACR Convergence 2026 on November 8
- CLN-049 Phase 1 AML dose-escalation update expected in December, supporting potential Phase 2 advancement
- Data timing creates near-term valuation catalysts, with clinical efficacy and safety outcomes remaining key risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cullinan Therapeutics, Inc. 8-K filings
Get the next CGEM 8-K as it lands
Follow CGEM for push alerts, or ask the research agent what this filing means.